Jeeva's virtual control room enables biopharma and medical device sponsors to conduct modern clinical trials from start to finish with real-time monitoring, enhancing efficiency, reducing risks, and cutting costs through a single login and subscription fee. The platform significantly alleviates the logistical burden for both participants and study teams, featuring bi-directional communication, eligibility screening, scheduling, electronic data capture (EDC), electronic clinical outcome assessments (eCOA), TeleVisits, and remote touchless electronic informed consent.

Powered by AI, the Jeeva platform automates and centralizes visit scheduling and protocol configuration, seamlessly integrating with modules like eConsent, ePRO/eCOA/EDC, TeleVisits/VideoVisits, adverse event capture with MedDRA coding, and a patient engagement portal with SMS, email, audio, and video communications, reminders, and notifications.

Dr. Harsha Rajasimha's personal experiences of losing a child born with a rare disease and a brother with a chronic disease inspired him to leverage his years of postdoctoral training at NIH and FDA to accelerate therapies for rare and common conditions. He recognized that technology alone is not the limiting factor; instead, patient-centered design driven by stakeholder needs and regulatory requirements is key to guiding their continuously learning digital platform. By digitizing and automating repetitive tasks and reducing logistical burdens on patients and study teams by over 70%, Jeeva accelerates the process of bringing new medicines and vaccines to patients by more than three times faster. Based in Virginia, the company's modular software-as-a-service platform is fully scalable and facilitates diverse patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device.